Pre-surgery treatment for stage II-III lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This study tests two investigational drugs (HLX43 and serplulimab) given before surgery to people with stage II to III non-small cell lung cancer (NSCLC). The goal is to see if these drugs can shrink the tumor and make it easier to remove completely during surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lung cancer called non-small cell lung cancer (NSCLC).
- Your cancer is at stage II or III (meaning it has spread to nearby lymph nodes but not to distant parts of the body).
- You have not had any previous treatment for this lung cancer, like chemotherapy or radiation.
- You are willing and able to have surgery to remove the cancer if the study treatment works.
- You are between 18 and 75 years old and in fairly good health (able to go about daily activities with little to no help).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of two cancer drugs (HLX43 and Serplulimab) for people with advanced solid tumors, especially those with a specific type of lung cancer (NSCLC) that has an EGFR mutation. The goal is to see if this combination can shrink tumors or slow their growth.
This trial studies whether giving a PD-1 antibody together with standard chemotherapy before surgery can improve outcomes for people with stage IIIB–IIIC non-small cell lung cancer. It aims to shrink or control the cancer and make treatment before surgery more effective.
This trial tests a new combination of two drugs for people with advanced lung cancer that has worsened after previous treatments like chemotherapy or immunotherapy. The goal is to see if this approach can help shrink tumors or slow the disease.
This trial tests a new drug, HLX43, for people with advanced non-small cell lung cancer that has not responded to standard treatments. It aims to see if HLX43 can help shrink or control the cancer.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial compares two immunotherapy drugs (serplulimab and nivolumab) given before surgery for people with resectable stage II-IIIA squamous non-small cell lung cancer. The goal is to see which works better to shrink the tumor and improve outcomes.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.